• IDEXX Laboratories management commentary attributed third-quarter fiscal 2026 organic revenue growth of 10% to diagnostic utilization, customer gains and innovation.
• Companion animal diagnostics recurring revenue rose 11% organically, led by volume gains, with approximately 4% global net price improvement.
• Operating margin increased 100 basis points to 33.1%, reflecting recurring revenue growth, productivity improvements and favorable product mix.
• Earnings per share rose 18% to $4.01, supported by operating profit growth.
• Management raised full-year EPS guidance to $14.96-$15.16, despite approximately $0.13 per share of dilution from the CoVet acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.